Associated tags: ATyr Pharma, SAN, Pharmaceutical industry, Small RNA, Research, Patient, Sarcoidosis, Biology, Fibrosis, Inflammation, Neuropilin, Safety, ILD, Systemic scleroderma, Scleroderma, Conference
Locations: LONDON, EUROPEAN UNION, WASHINGTON, UNITED STATES, SAN DIEGO, CA, US, NEW YORK, NY, FL, EUROPE, JAPAN
In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the RBC and Jefferies conferences.
Key Points:
- In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the RBC and Jefferies conferences.
- A webcast of the RBC and Jefferies events will be available on the Investor’s section of the company’s website at www.atyrpharma.com .
- Following the events, a replay of the RBC and Jefferies presentations will be available on the aTyr website for at least 90 days.
- aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation.
FGFR4,
Patient,
EAP,
ATS,
FGF2,
Investment,
Safety,
Poster,
Research,
Sarcoidosis,
PDT,
Conference,
Biologics license application,
ILD,
ATyr Pharma,
BLA,
Small RNA,
Clinical trial,
American Thoracic Society,
SAN,
Pharmaceutical industry SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced first quarter 2024 results and provided a corporate update.
Key Points:
- Ended the first quarter 2024 with $87.7 million in cash, cash equivalents, restricted cash and investments.
- SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced first quarter 2024 results and provided a corporate update.
- Based on current enrollment projections, the Company anticipates completing enrollment in the study in the second quarter of 2024.
- G&A Expenses: General and administrative expenses were $3.5 million for the first quarter 2024.
SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcoming investor conferences scheduled to take place in April 2024.
Key Points:
- SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in two upcoming investor conferences scheduled to take place in April 2024.
- Details of the conferences appear below:
For more information on how to register, please contact your Evercore ISI or Piper Sandler representative.
- aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation.
- tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans.
PDT,
Research,
Conference,
Interest,
ATS,
Biologics license application,
Patient,
SAN,
Howard University,
Knowledge,
EAP,
ATyr Pharma,
EDT,
NRP2,
American Thoracic Society,
Downstream,
Investment,
Clinical trial,
Small RNA,
Neuropilin,
Myelocyte,
Safety,
Sarcoidosis,
Immune system,
FGF2,
FGFR4,
BLA,
Pharmaceutical industry SAN DIEGO, March 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2023 results and provided a corporate update.
Key Points:
- SAN DIEGO, March 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2023 results and provided a corporate update.
- Based on current enrollment projections, the Company anticipates completing enrollment in the study in the second quarter of 2024.
- Interested parties may access the call by registering here in order to obtain a dial in, personalized passcode and webcast information.
- Links to a live audio webcast and replay may be accessed on the aTyr website Events page at: http://investors.atyrpharma.com/events-and-webcasts .
Retrieved on:
Wednesday, February 28, 2024
Management will host a conference call and webcast to review the results and provide an operational update.
Key Points:
- Management will host a conference call and webcast to review the results and provide an operational update.
- Conference Call and Webcast Details:
Participants who wish to join the conference call by telephone must register at the above dial-in registration link in order to receive the dial-in number and a personalized PIN code that will be required to access the call.
- Participants may join the live webcast by accessing it at the above webcast registration link on the aTyr Events page.
- For more information or questions, please contact aTyr’s investor relations team at [email protected] .
Retrieved on:
Wednesday, February 21, 2024
SAN,
Sarcoidosis,
Scar,
Small RNA,
Pi,
ATyr Pharma,
FDA,
Inflammation,
Food,
Scleroderma,
Risk,
Myelocyte,
Health,
Safety,
Principal investigator,
Expanded access,
Neuropilin,
Systemic scleroderma,
ILD,
OLE,
Patient,
Fibrosis,
Clinical trial,
EAP,
Pharmaceutical industry SAN DIEGO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the Company), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced plans to initiate an Individual Patient Expanded Access Program (EAP) for its lead therapeutic candidate, efzofitimod, for patients with pulmonary sarcoidosis. The Individual Patient EAP is intended to allow access for patients who complete the Phase 3 EFZO-FIT™ study and wish to receive treatment with efzofitimod outside of the clinical trial.
Key Points:
- Individual Patient EAP allows access to efzofitimod for patients who complete the Phase 3 EFZO-FIT™ study in pulmonary sarcoidosis.
- Company initiating program based on blinded EFZO-FIT™ study investigator and patient participant feedback.
- The Individual Patient EAP is intended to allow access for patients who complete the Phase 3 EFZO-FIT™ study and wish to receive treatment with efzofitimod outside of the clinical trial.
- “We are pleased to make efzofitimod available to patients beyond the duration of the EFZO-FIT™ clinical trial through this Individual Patient EAP,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr.
Patient,
Medicine,
Fibrosis,
Faculty,
Scar,
SAN,
NRP2,
Scleroderma,
University,
Small RNA,
Disease,
Neuropilin,
Nebraska Medicine,
ATyr Pharma,
Inflammation,
Systemic scleroderma,
Sarcoidosis,
Myelocyte,
Immune system,
Pharmaceutical industry SAN DIEGO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present two posters at the Keystone Symposia on Myeloid Cell Diversity: From Fundamental Biology to Disease States, which is being held January 28 – 31, 2024, in Banff, Alberta, Canada.
Key Points:
- Findings further demonstrate that efzofitimod modulates myeloid cells via the neuropilin-2 (NRP2) receptor to promote a unique anti-inflammatory mechanism.
- Role of NRP2 in immune system validated by activity of NRP2 blocking antibody in preclinical models.
- aTyr Pharma, San Diego; Faculty of Health and Medical Sciences, Copenhagen, Denmark.
- These forms of ILD have limited therapeutic options and there is a need for safer and more effective, disease-modifying treatments that improve outcomes.
Retrieved on:
Thursday, January 18, 2024
Mortality,
ILD,
Patient,
Outline of health sciences,
Wayne A. I. Frederick,
Sarcoidosis,
Research,
Biology,
Fibrosis,
Associate,
Scar,
ACS,
Dean (education),
Howard University,
SAN,
Knowledge,
University,
National academy,
Humana,
Scleroderma,
Business,
Small RNA,
American Surgical Association,
Human,
Disease,
American College,
Neuropilin,
ATyr Pharma,
Health,
Inflammation,
Organization,
MD Anderson Cancer Center,
Systemic scleroderma,
College,
Howard University Hospital,
Abstract,
Myelocyte,
American Cancer Society,
Pharmaceutical industry Dr. Frederick is President Emeritus of Howard University, having served as President from 2014 to 2023.
Key Points:
- Dr. Frederick is President Emeritus of Howard University, having served as President from 2014 to 2023.
- “We are honored to welcome a distinguished physician executive such as Dr. Frederick as an advisor to aTyr,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr.
- He is also the distinguished Charles R. Drew Professor of Surgery at the Howard University College of Medicine and a practicing cancer surgeon at Howard University Hospital.
- Dr. Frederick earned a B.S., M.D., and completed his surgical residency training at Howard University Hospital.
Retrieved on:
Monday, November 13, 2023
NRP2,
SAN,
Neuropilin,
Inflammation,
Scar,
Sarcoidosis,
ILD,
Scleroderma,
Systemic scleroderma,
Patient,
Myelocyte,
Rheumatoid arthritis,
American College of Rheumatology,
ATyr Pharma,
American College,
Small RNA,
ACR,
Poster,
Fibrosis,
Pharmaceutical industry The poster will be available on the aTyr website once presented.
Key Points:
- The poster will be available on the aTyr website once presented.
- The poster presents findings from preclinical models of rheumatoid arthritis (RA) and RA-associated ILD (RA-ILD), where NRP2, efzofitimod’s binding partner, is known to be expressed on pro-inflammatory synovial macrophages.
- An animal knockout model for NRP2 demonstrated that NRP2 deficiency exacerbated disease pathology in preclinical models of inflammatory disease.
- These forms of ILD have limited therapeutic options and there is a need for safer and more effective, disease-modifying treatments that improve outcomes.
Retrieved on:
Thursday, November 9, 2023
NRP2,
Research,
Safety,
SAN,
Neuropilin,
PST,
D,
BLA,
Sarcoidosis,
ILD,
Scleroderma,
International,
Investment,
Systemic scleroderma,
ERS,
Clinical trial,
Patient,
European Respiratory Society,
DSMB,
Rheumatoid arthritis,
ATyr Pharma,
American College,
American College of Rheumatology,
Small RNA,
The Journal,
Frontiers,
Skin,
ACR,
Poster,
Biologics license application,
Pharmaceutical industry,
Pharmacology,
Kyorin SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced third quarter 2023 results and provided a corporate update.
Key Points:
- Ended the third quarter of 2023 with $105.6 million in cash, cash equivalents and investments.
- SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced third quarter 2023 results and provided a corporate update.
- Based on current enrollment projections, the Company expects to complete enrollment in the study early in the second quarter of 2024.
- G&A Expenses: General and administrative expenses were $2.6 million for the third quarter of 2023.
